Participants considered trifluridine-tipiracil the most suitable treatment option for an elderly patient with a KRAS-wildtype tumor who has hypertension and type 2 diabetes, previous side effects (neuropathy, rash, diarrhea, and stomatitis), limited caregiver support, and hospital accessibility issues, with 70% citing this as their preferred treatment option. Here, KRAS is linked to neuropathy.